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Selective inhibition of the mitochondrial permeability transition pore protects against 
neuro-degeneration in experimental multiple sclerosis. 
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ABSTRACT 
The mitochondrial permeability transition pore 
(PT pore) is a recognised drug target for 
neurodegenerative conditions such as multiple 
sclerosis (MS) and for ischaemia–reperfusion 
injury in the brain and heart. The peptidylprolyl 
isomerase, cyclophilin D (CypD, ppif) is a positive 
regulator of the pore and genetic downregulation 
or knockout improves outcomes in disease models. 
Current inhibitors of peptidylprolyl isomerases 
show no selectivity between the tightly conserved 
cyclophilin paralogs and exhibit significant off 
target effects, immune-suppression and toxicity. 
We therefore designed and synthesised a new 
mitochondrially-targeted CypD inhibitor, JW47, 
using a quinolinium cation tethered to 
cyclosporine (CsA).  X-ray analysis was used to 
validate the design concept and biological 
evaluation revealed selective cellular inhibition of 
CypD and the PT pore with reduced cellular 
toxicity compared to CsA.  In an experimental 
autoimmune encephalomyelitis disease model of 
neurodegeneration in multiple sclerosis (MS), 
JW47 demonstrated significant protection of axons 
and improved motor assessments with minimal 
immunosuppression.  These findings suggest that 
selective CypD inhibition may represent a viable 
therapeutic strategy for MS and identify 
quinolinium as a mitochondrial targeting group for 
in vivo use. 
 
A considerable body of evidence points to a role 
for the mitochondrial permeability transition (PT) 
pore in neurodegenerative and ischaemic cell 
death.  The peptidylprolyl cis-trans isomerase 
cyclophilin D (CypD, PPIF),which is genomically 
expressed and imported into mitochondria, is 
consistently implicated as a key player in the 
sequence of events leading to PT pore opening and 
eventual cell death by necrosis.  The PT pore 
forms under conditions of oxidative stress, low 
adenine nucleotide concentrations and 
mitochondrial Ca
2+
 overload and results in free 
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passage of low molecular weight solutes (<1500 
Da) and some proteins across the inner 
mitochondrial membrane. Under these conditions, 
mitochondrial proton gradient and membrane 
potential (ψm) is dissipated, leading to ATP 
hydrolysis by the reversal of the F1FO ATP 
synthase and consequent cellular energy depletion, 
resulting in cell death.  Recent studies point to the 
F1FO ATP synthase of mitochondria as being the 
major component of the PT pore (1), but the 
subunits involved and the exact pore forming 
mechanism is controversial (2-4). CypD binds to 
the lateral stalk of the F1FO ATPase and positively 
regulates pore opening (5,6). In CypD knockout 
animals, the pore is desensitized to Ca
2+
, in an 
inorganic phosphate(Pi)-dependent manner (7). 
There is mounting evidence that CypD is key in 
mediating Ca
2+
 induced pore opening, and its 
absence e.g. in PPIF knockout animals, 
desensitizes the pore to Ca
2+
, in an inorganic 
phosphate(Pi)-dependent manner (7). 
Pharmacological inhibition of the pore offers a 
route to cyto- and neuroprotection.  
Multiple sclerosis (MS) is an immune-
mediated demyelinating and neurodegenerative 
disease of the central nervous system and the 
commonest form of non-traumatic disability in 
young adults (8).  Whilst relapsing autoimmunity 
in MS can be controlled by peripheral 
immunomodulatory agents, progressive disability 
that results from neurodegeneration is so far, 
untreatable(8,9). Neurodegeneration in MS is 
associated with the influence of centrally-active 
inflammatory responses(10,11). This may relate to 
metabolic and energy stresses in nerves within the 
inflammatory penumbra that drive nerve loss 
during neuroinflammation in MS and other 
neurodegenerative diseases(12-14). Mitochondrial 
dysfunction and the irreversible opening of the 
PTP, is now recognised as a key player in the 
degeneration of axons (15). In MS lesions 
(12,16,17),the PT pore induced ATP deficit may 
result in the inactivation of energy-dependent 
sodium/potassium pumps, leading to sodium 
loading and the reversal of the sodium-calcium 
exchanger that causes toxic accumulation of 
calcium ions and the induction of cell death 
effector pathways(16,18). 
CypD is highly expressed in a subset of 
astrocytes , microglia and neurons (19) where it 
may contribute to excitotoxicity and cell death in 
MS lesions (12,16,17). CypD knockout mice show 
a less severe phenotype compared to wild type in 
the experimental autoimmune encephalomyelitis 
(EAE) model of MS(20,21). CypD knockout 
mouse studies in models of traumatic brain injury 
(22,23), Alzheimer’s disease (24,25), Parkinson’s 
disease (26), amyloid lateral sclerosis (27)  and 
Huntington’s disease (28,29), all show a benefit 
compared to wild type mice. The PT pore is also 
implicated in ischaemia–reperfusion injury in the 
adult brain (30)and in the heart where CypD 
ablation, or RNAi knockdown (31,32) provide 
cardio-protection(33,34).  A selective inhibitor of 
PT pore opening could therefore have therapeutic 
applicability in a range of diseases particularly MS 
where the progressive disability that results from 
neurodegeneration is so far, untreatable(8,9). 
Cyclosporine (cyclosporin A, CsA, Fig. 
1A) is a non-selective cyclophilin inhibitor.  CsA 
forms a ternary complex with the cytoplasmic 
CypA and calcineurin leading to inhibition of 
calcineurin signaling. This blocks downstream 
cytokine production associated with immune cell 
activation(35) (36) and makes CsA a potent and 
clinically useful, immuno-suppressive. Chemical 
modification to remove calcineurin binding is 
relatively straightforward, but selectivity for the 
different cyclophilin proteins is difficult owing to 
their close structural and sequence similarity(37). 
Neuroprotective actions of CsA via action on 
mitochondrial CypD are reported: case studies and 
clinical trials support a neuroprotective effect 
(38,39), while clinical studies with CsA in 
traumatic brain injury are in progress 
(NCT01825044). In vitro CsA shows cytotoxicity 
and multiple effects on cell health parameters, 
while problems with the clinical use of CsA are 
nephrotoxicity(35,39), bilirubinaemia and liver 
toxicity(40) which can require withdrawal of the 
drug.  These properties combine to make CsA a 
less than ideal drug candidate for neuroprotection.  
A potential solution to the problem of targeting the 
individual cyclophilins is to enable mitochondrial 
localization. Triphenylphosphonium (TPP
+
) is the 
archetypal mitochondrial targeting, lipophilic 
cation(41) and has been used in humans for 
targeting a co-enzyme Q analogue to 
mitochondria(42). TPP
+
 has non-ideal 
pharmaceutical properties however, including: a) 
high molecular weight and lipophilicity 
contributing to a lack of “drug likeness”, b) 
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mitochondrial toxicity (43,44), d) effects on 
respiration(45) and c) non-ideal biodistribution 
(46). We have previously shown that TPP
+
 can be 
linked to CsA at the [Sar]
3
 position to provide a 
molecule with immunosuppression blocked and 
improved cytoprotection in vitro (36,47). 
Here we investigated the quinolinium cation as a 
replacement for triphenylphosphonium. We 
observed that quinolinium is an effective 
mitochondrial targeting group: A prototype 
molecule JW47, was shown to be more potent at 
blocking the PT pore and demonstrated less cell 
toxicity than CsA.  In vivo JW47 was less 
immunosuppressive than CsA and notably 
achieved significant neuroprotection in an EAE 
model of MS in mice.  
 
Experimental procedures 
Chemistry. All commercially available 
solvents and reagents were used without further 
treatment as received unless otherwise noted. 
NMR spectra were measured with a Bruker DRX 
500 or 600 MHz spectrometer; chemical shifts are 
expressed in ppm relative to TMS as an internal 
standard and coupling constants (J) in Hz. LC-MS 
spectra were obtained using a Waters ZQ2000 
single quadrupole mass spectrometer with 
electrospray ionisation (ESI), using an analytical 
C4 column (Phenomenex Gemini, 50 x 3.6 mm, 5 
μm) and an AB gradient of 50–95 % for B at a 
flow rate of 1 mL/minute, where eluent A was 
0.1:5:95 formic acid/methanol/water and eluent B 
was 0.:5:95 formic acid/water/methanol. High 
resolution mass spectra were acquired on a Waters 
LCT time of flight mass spectrometer with 
electrospray ionisation (ESI) or chemical 
ionization (CI).  
Preparation of JW47, 1-(pent-4-
enyl)quinolinium To a solution of quinoline (1 g, 
7.74 mmol) in EtOAc was added 5-bromo-pent-1-
ene (1.27 g, 8.51 mmol) and this mixture was 
heated to reflux overnight. The mixture was 
allowed to cool before concentration under 
reduced pressure. The product was isolated as a 
light brown oil (1.54 g, 99%). 
LCMS (m/z): [MH]
+
 calcd. for C14H16N+, 198.29; 
found 198.10. NMR δH (Acetone-d6, 600 MHz): δ 
10.26 (dd, J = 5.8, 1.4 Hz, 1H), 9.41 (d, , J = 8.4 
Hz, 1H), 8.80 (d, J = 9.0 Hz, 1H), 8.58 (dd, J = 
8.2, 1.3 Hz, 1H), 8.36 (dd, J = 8.3, 1.5 Hz, 1H), 
8.27 (dd, J = 8.3, 5.8 Hz, 1H), 8.13 – 8.08 (m, 
1H), 5.90 (dd, J = 17.0, 10.3 Hz, 1H), 5.49 – 5.42 
(m, 2H), 5.09 (ddd, J = 17.1, 3.4, 1.6 Hz, 1H), 
1H), 5.01 – 4.96 (m, 1H), 2.41 – 2.35 (m, 2H), 
2.34 – 2.26 (m, 2H). 
[Gly-(1S,2R,E)-8-quinolinium-1-hydroxy-
2-methyloct-4-ene]
1
 CsA  (JW47)  To a solution of 
Cyclosporin A (75 mg, 0.06 mmol) in DCM (2 
mL) was added 1-(pent-4-en-1-yl)quinolinium (23 
mg, 0.072 mmol) and Hoveyda-Grubbs 2
nd
 
generation catalyst (7 mg, 0.01 mmol, 17mol%). 
The reaction was stirred in the microwave at 90 
o
C 
for 30 minutes and then allowed to cool. 
Triethylamine was added to the mixture and then 
stirred overnight with excess P(CH2OH)3 to 
coordinate the ruthenium catalyst. This was then 
washed away with brine and water before the 
mixture was passed through a Stratospheres PL 
Thiol MP SPE cartridge (polymer Lab, Varian Inc) 
to remove any remaining catalyst. The crude 
product was purified by flash reverse-phase 
chromatography (MeOH:H2O:formic acid) to give 
JW47 as a brown solid (15 mg, 17%). HRMS 
(m/z): [MH]
+
 calcd. for C65H115N11O12, 1357.92; 
found 1357.95. NMR δH (CDCl3, 600 MHz):  δ 
3.49 (s, NMe, 3H), 3.40 (s, NMe, 3H), 3.20 (s, 
NMe, 3H), 3.12 (s, NMe, 3H), 3.08 (s, NMe, 3H), 
2.71 (s, NMe, 3H), 2.68 (s, NMe, 3H). 
NMR δC (CDCl3, 150 MHz): 39.35, 39.19, 33.67, 
31.25, 30.10, 30.01, 29.79 (7 x N-Me). 
 Protein expression. The CypD expression 
system was constructed as described by Schlatter 
et al (48). Briefly, codon optimised DNA encoding 
the CypD-K133I gene was cloned into pET11a 
(Novogen) digested with NdeI and BamHI. The 
resulting plasmid was used to transform 
BL21(DE3)pLysS.  Expression cultures were 
grown at 37°C in Luria–Bertani (LB) medium, at 
A600 of 0.6, the cells were induced with 1 mM 
isopropyl-d-1-thiogalactopyranoside (IPTG). The 
cultures were then incubated at the same 
temperature for another four hours and the cells 
harvested by centrifugation. The cell pellet was re 
suspended in lysis buffer (100mM Tris/HCl pH 
7.8, 2mM EDTA, 2mM DTT supplemented with 
EDTA-free protease inhibitor tablets (Roche)) and 
the cells lysed by sonication. The sonicate was 
clarified by centrifugation and the CypD was 
isolated as previously described (49) using IEC 
with SP-Sepharose followed by Q-sepherose and 
finally SEC with Superdex200. The protein was 
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stored in SEC buffer (50mM potassium/sodium 
phosphate pH 7.3, 100mM NaCl, 2mM EDTA, 
0.02% sodium azide) at 4°C. 
 Crystallography. Crystals were grown 
using the hanging drop method as previously 
described (50); drops contained a 50:50 mix of 
protein solution (30 mg/ml CypD in gel filtration 
buffer) and reservoir solution. The best crystals 
were obtained with a reservoir solution consisting 
of 23% polyethylene glycol (PEG3350), 50 mM 
sodium-citrate buffer at pH 2.9 as precipitant 
solution. Prior to data collection the crystals were 
cooled to 100K using 35% PEG 3350 in sodium-
citrate buffer at pH 2.9 as the cryoprotectant. Data 
were collected on beam-line i04 at Diamond Light 
Source. Phases were determined by the molecular 
replacement method using the PHASER (51) from 
the CCP4 suite of programmes (52); the CypD-
cyclosporin A structure, pdb code 2z6w, was used 
as the search model, but with the cyclosporin A 
removed from the model. The model was refined 
using cycles of the programme REFMAC (53)
,
(54) 
(with aniosotropic B-factors and Babinet bulk 
solvent modelling), interspersed with manual 
checks and model building with COOT (55). The 
final resolution cut-off was determined during 
refinement. Ligand topologies were generated with 
PRODRG2 (56). The final model was validated 
with PROCHECK (57) and SFCHECK (54) and 
finally MOLPROBITY (58). Refinement statistics 
are presented in Table 1. The illustrations were 
produced with the PyMOL molecular graphics 
system (Shrödinger LLC). 
 Fluorescence Polarization assay. 
Fluorescence polarization (FP) is inversely related 
to the molecular rotation of the fluorophore. 
Fluorophores linked to small molecules tumble 
faster and emit less polarized fluorescence than 
fluorophore-small molecules bound to proteins. FP 
is a convenient technique to measure affinity of 
ligands to cyclophilins (59,60).  We synthesized a 
new fluorescein-PEG-CsA ligand as the probe 
(vide supra) and we determined the binding of our 
novel ligands to CypD and CypA. 
Titration of a single probe concentration against 
different enzyme concentrations was used to 
determine the dissociation constant (Kd).  From 
this we also determined the enzyme concentration 
that would give a high enough polarization signal 
to measure binding affinities. The inhibitor 
constants (Ki), were calculated with the equation 
below (61).  
Ki = 
[𝐼]50
[𝐿]50
𝐾𝑑
+
[𝑃]0
𝐾𝑑
+1
 
Where [I]50 is the concentration of the unlabelled 
compound at 50% inhibition, [L]50 is the 
concentration of the free probe-cyclophilin 
enzyme at 50% inhibition, [P]0 is the 
concentration of the free protein at 0% inhibition, 
and Kd is the dissociation constant of the probe-
protein complex 
Assays were conducted in 384-black low flange 
non-binding microtiter plates (Corning, 
Tewksbury, MA, USA). A total solution of 80 µL 
was used consisting of 3 components, fluorescent 
cyclosporine probe (FP-CsA) 45 nM, enzyme 40 
nM, inhibitor (10-10000 nM). At least 3 replicates 
were used for each experiment. DMSO% in total 
solution should remain lower than 1%. FP-probe.  
Enzyme, inhibitor and FP-CsA are incubated in 
the OmegaFluostar at room temperature for 30 
minutes, FP-CsA (40 µL) was added last. 
Measurements were taken after gain adjustment of 
control sample and 30 min incubation, with a 
xenon flash light with filter settings for 485 
excitation and 520 emission.  
Mitochondrial isolation. Subcellular 
fractionation was performed as previously 
described (62). Briefly, C57BL/6J WT or 
cypD(63) -/-  male mice of 3-6 months were 
sacrificed by cervical dislocation, and their liver 
was removed and placed immediately into ice-cold 
isolation buffer (250mM mannitol, 5 mM HEPES, 
0.5 mM EGTA, pH 7.4).  At 4°C, the liver was 
rinsed in PBS to remove excess blood, and any fat 
and connective tissue was eliminated.  PBS was 
then replaced with isolation buffer containing 1 
mM PMSF, and the liver was chopped into pieces 
(approximately 2 mm in length).  Tissue was then 
homogenized in this solution until no solid matter 
remained, and then centrifuged at 800g for 10 
minutes at 4°C.  The nuclear pellet was then 
discarded, and the post nuclear supernatant 
retained, and centrifuged at 10300G for another 10 
minutes at 4°C.  The post-mitochondrial 
supernatant was discarded, and the mitochondrial 
pellet was resuspended in isolation buffer and 
PMSF, and kept on ice.  Protein levels were 
quantified using a ThermoScientific BCA protein 
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quantification assay, as per manufacturer’s 
instructions.  
Calcium retention capacity assay. Isolated 
mitochondria were resuspended (500 µg 
protein/ml) in MSK buffer (75 mM mannitol, 25 
mM sucrose, 5 mM potassium phosphate 
monobasic, 20 mM  Tris-HCl, 100 mM KCl, and 
0.1% bovine serum albumin, pH 7.4) 
supplemented with 10 mM succinate, 1 µM 
rotenone and 1 µM Fluo5N. 200 µl mitochondrial 
suspension per well was used in 96 well 
microplates. Compounds were incubated for ten 
minutes before the plate was assayed in a Fluostar 
Optima plate reader, using Ex/Em filters at 
480/520 nM; CaCl2 was injected approximately 
every 6.5 minutes  for 80 minutes (12 total 
injections, final concentration of 75 µM). To 
calculate % inhibition of Ca
2+
 induced pore 
opening, first areas under each curve were 
calculated, and controls without CaCl2 addition 
were subtracted as background. The background 
corrected values were then expressed as the 
fraction of controls without mitochondria, 
representing the total amount of Ca
2+
 added, 
unbuffered by mitochondria.  Percentage 
inhibition for each [compound] was then 
calculated as the % of the corresponding value for 
the untreated condition. Significance was assessed 
by one way ANOVA, in comparison to CsA 
control.  For experiments with CypD -/- mice, 
100ul mitochondrial suspension per well was used.  
CaCl2 was injected approximately every 6.5 
minutes for 135 minutes (20 total injections, final 
concentration of 266 µM).  Data were background 
corrected and expressed as the fraction of controls 
without mitochondria, and then normalised to the 
wild type no drug condition.  Significance was 
assessed by one way ANOVA.  
  
Respirometry. Oxygen consumption was measured 
using Oroboros Oxygraph-2K as previously 
described (62).  Prior to the assay, the Oxygraph 
chambers were calibrated with Miro5 buffer (0.5 
mM EGTA, 3 mM MgCl2.6H2O, 60 mM K-
lactobionate, 20 mM taurine, 10 mM KH2PO4, 20 
mM HEPES, 110 mM sucrose, 1 g/l BSA 
(essentially fatty acid free)).  Isolated 
mitochondria were suspended in Miro5 (at 100-
200 µg/ml), loaded into the chamber together with 
substrates (malate, 2 mM; glutamate, 10 mM), and 
the O2 flow signal was allowed to stabilise to the 
basal respiration rate (approx. 10 min).  
Compounds were added to the chambers at the 
following concentrations and order: 
DMSO/CsA/JW47 (concentration as indicated) to 
produce basal rate after compound (basal AC), 
ADP (2.5 mM) to give state 3 respiration, 
oligomycin (2.5 µ M) to give leak respiration, 
FCCP (titrated to produce maximal respiratory 
capacity), and antimycin A (2.5 µM) to give non-
mitochondrial respiration.  Data were analysed by 
subtracting the antimycin A respiration rate to give 
mitochondrial specific O2 flow, and were then 
expressed as a percentage of the basal O2 flow.  
Significance was assessed by one way ANOVA, in 
comparison to DMSO control. 
Measurement of mitochondrial membrane 
potential. Rat cortical neurons, cultured for 8-
9days, were incubated for 40 minutes at 37°C with 
the cell permeant cationic dye 
tetramethylrhodamine methyl ester (TMRM, 25 
nM), and fluorescence was measured using the 
ImageXpress Micro XL system (Molecular 
Devices).  Fluorescence was measured for 7 
minutes prior to addition of DMSO, CsA or JW47 
(both at 40 nM and 1 µM), and then for a further 
50 minutes before the addition of the 
mitochondrial uncoupler carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP, 5 
µM) as a positive control.  The minimum value 
after the addition of compound (prior to the 
addition of FCCP) was taken, and this was 
expressed as a % (using baseline as 100% and 
FCCP as 0%), and then normalized to DMSO 
(100%).  Significance was assessed by one-way 
ANOVA, in comparison to DMSO control.   
Measurement of mitochondrial membrane 
potential (ex vivo). Freshly isolated mouse liver 
mitochondria were suspended in MSK buffer 
containing 10ug/ml rhodamine123 (dequench 
mode), at a concentration of 500ug/ml, and plated 
in an opaque black 96 well plate.  Baseline 
fluorescence was then measured every 60 seconds 
for 5 minutes in a Fluostar Optima 
(Ex480/Em520) before manual addition of 
compounds (concentrations as specified).  
Fluorescence measurements were continued for 45 
minutes until the addition of 2uM FCCP, followed 
by a further 10 minutes of fluorescence readings.   
ATP production. Freshly isolated 
mitochondria were resuspended in MSK buffer 
(containing10mM glutamate and 2mM malate) at 
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1mg/ml and plated in opaque white 96 well plates, 
or for neuronal assays, neurons were used 9 days 
after plating at 15000 cells/well.  Drugs were 
added at the concentrations specified, and for 
mitochondrial assays were incubated for ten 
minutes before addition of ADP (5mM), followed 
by another 45 minutes.  For neuronal assays, drugs 
were added in neurobasal medium and incubated 
for 60 minutes.  Cell Titer Glo reagent was then 
added, and the plate shaken for 2 minutes in the 
dark to lyse cells/mitochondria and release ATP.  
The plates were incubated a further ten minutes 
and then luminescence values read using an 
Optima FluoStar. ATP production: Data were 
normalised to DMSO control, and significance 
assessed by one way ANOVA. Brain mitochondria 
are insensitive in this assay.  
Cytotoxicity in HepG2 cells. HepG2 cells 
were seeded in black, clear-bottom 96-well tissue 
culture plates at a density of 3000 cells per well. 
The cells were incubated for 24 h in culture 
medium and then exposed (in three replicates) to 
increasing doses of test compound or to vehicle 
control (0.5% DMSO). The cells were exposed for 
72h before running the high content screening 
(HCS) assays. The HCS assay was multiplexed to 
determine mitochondrial membrane potential and 
mitochondrial mass using MitoTracker® (Life 
Technologies), cytochrome C release (antibody, 
Abcam), membrane permeability, YO-PRO
TM
-1 
(Life Technologies). Cell count, nuclear size and 
DNA structure were also measured Hoechst 33342 
(Life Technologies). Following staining of the 
HepG2 cells fluorescence was analyzed by image 
acquisition with a Thermo Fisher Cellomics® 
ArrayScanVTI High Content Screening Reader 
(ThermoFisher Scientific Inc., Waltham, MA) and 
vHCS
TM
view software (ThermoFisher Scientific 
Inc.). Twenty fields were imaged per well using a 
10x wide field objective. The image acquisition 
data were normalized to vehicle control values. 
Dose-response curves were defined and evaluated 
with the following equations: 
 
(1) ξ(C; c; ω) ≡ (ln(C) – c)/ω; 
(2) t(ξ) ≡ (1 + tanh(ξ))/2;  
(3) R(t;R0;R∞) ≡ R0(1 - t) + R∞t; 
 
In which C represents the test compound 
concentration and R0, R∞, c, and ω are fitting 
parameters. The final response at a given 
concentration C is expressed as R(t(ξ(C; c; 
ω));R0;R∞). It was restricted such that ω > 0, 
which implies R  R0 as C  0 and R  R∞ as 
C  ∞. The coefficient of determination (R2) was 
calculated for each compound and dose-response 
curve. An R
2
 value of greater than 0.65 was used 
as QC criteria and was required in all response 
curves. 
Cell based assay for CypA activity. VSV-
G pseudotyped GFP-encoding HIV-1 vector was 
prepared by triple plasmid transfection of 293T 
cells with Fugene 6 (Roche) as follows. Confluent 
293T cells in a 10cm dish were transfected with a 
mixture of 10 µl Fugene-6 in 200µl OptiMEM 
(Gibco), with 1 µg of pMDG VSV-G expression 
vector (64), 1 µg of p8.91 HIV-1 gag-pol 
expression vector (65), and 1.5 µg of lentiviral 
expression vector encoding enhanced GFP protein, 
CSGW (66). Viral supernatant was collected 48h 
post transfection and stored at -80
o
C. 
To generate CRFK cells stably expressing N-
terminally HA-tagged TRIM-CypA from an EXN-
based vector, MLV vector was prepared as above, 
using pMDG, CMVi MLV gag-pol expression 
vector, and gammaretroviral expression vector 
encoding a fusion protein comprising human 
CypA downstream of owl monkey TRIM5 RBCC 
(EXN-TRIM-CypA) (67). CRFK cells, which are 
null for TRIM5 activity (68) were then 
transduced with vector, followed by selection of 
cells in 1 mg/ml G418 (Invitrogen). 
To test for the ability of drug to rescue HIV-1 
infectivity in the presence of TRIM-CypA, CRFK 
cells were infected with a single dose of virus that 
infected around 20% of the cells, in the presence 
of DMSO, CsA (0.3-10 µM) or JW47 (0.6-20 
µM). Infectivity was measured by flow cytometry, 
48 hrs post infection. 
 Pgp activity. Assessment of drug transporter 
activity was made using the Pgp-GloTM assay 
(Promega, Madison, WI, USA) containing 
recombinant human ABCB1 in membranes and 
according to the manufacturer’s instructions. 
Briefly, samples were pre-incubated with ATP 
before incubation with 100 mM compound or 
positive control. The residual ATP was assayed by 
luciferin bioluminescence. 
In vitro mitogenic T cell stimulation. 
Spleens were isolated from ABH mice and tissue 
was homogenized through a cell strainer (BD 
Biosciences, Oxford, UK) into Dulbecco’s 
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modified eagle medium (DMEM; Invitrogen, 
Paisley, UK) containing 10 % foetal calf serum 
(FCS, Gibco, Invitrogen), 2 mM L-glutamine 
(Invitrogen, UK),  100 U/ml penicillin and 100 
μg/ml streptomycin (Invitrogen) and 50 μM 2-
mercaptoethanol (Invitrogen).  Cells were 
centrifuged at 500g for 5min and erythrocytes 
were lysed using 0.87 % ammonium chloride 
following incubation for 5 min at 37˚C. Cells were 
washed and viable cells counted using trypan blue 
(Sigma Aldrich, Poole, UK) exclusion. 4 x 10
-5
 
cells/well were incubated 96 well microtest U-
bottom plates (Falcon BD, Oxford UK) in final 
volume of 200μl DMEM medium.  Cells were 
incubated with either ten-fold dilutions (range 
10nM-10μM) of CSA (Sandoz, Basel, CH) or 
JW47 diluted in DMEM medium from a 50mM 
stock in dimethyl sulphoxide. Cells were 
incubated with either: 5μg/ml concanavalin A 
(Con A. Sigma Aldrich) mitogen; 0.5μg/ml 
mitogenic mouse CD3 and mouse CD28-specific 
antibodies (Pharmingen, Oxford, UK). The cells 
were incubated in 37˚C during 18-22 h, before 
addition of 1 μCi3H-thymidine (PerkinElmer, MA, 
USA) per well. After additional incubation in 16-
20 h the 96-well plates (Microtest U-bottom, 
Falcon BD) were harvested (Harvester 96, Mach 
III M, TOMTEC) onto glass-fibre filters 
(PerkinElmer). After drying, a scintillation sheet 
(MeltiLexA; PerkinElmer) was melted onto the 
filter using a hot plate (RET Basic, IKA, 
Germany).  Samples were analysed using 
scintillation counting (MicroBeta Plus, Liquid 
Scintillation Counter, PerkinElmer, WallacOy, 
Finland) and 
3
H-thymidine incorporation was 
assessed in at least triplicate samples.  
Myelin antigen-induced T cell 
proliferation. ABH mice were injected 
subcutaneously in the flank with 100 μg myelin 
oligodendrocyte glycoprotein (MOG) peptide 
residues 35-55 (Cambridge Research 
Biochemicals Ltd, Billingham, UK) emulsified in 
Freunds adjuvant containing 200 μg 
Mycobacterium tuberculosis H37Ra (DifcoBacto, 
MI, USA) on day 0 and 7 (69). Spleens were 
collected and prepared and analysed as above 
except that mitogens were replaced with 5μg/ml 
MOG 35-55 peptide and cells were incubated for 
72h before addition of tritiated thymidine. 
Pharmacokinetic analysis. ABH mice 
(n=4) were injected intraperitoneally with 0.1 ml 
of either 10 mg/kg JW47. Animals were killed 2h 
and 4h later with C02 overdose and blood was 
immediately collected from the heart following 
death and added to Microtainer (BD, Oxford, UK) 
tubes, centrifuged using an Eppindorf microfuge 
and plasma collected. Following the remove of 
blood the brain was rapidly (<30s) dissected from 
the skull and stored at -80°C prior to analysis by a 
Contract research Organisation (CRO) using liquid 
crystal mass spectroscopy. 
In vivo T cell proliferation.The contact 
sensitiser 4-ethoxymethylene-2-phenyl-2-
oxazolin-5-one (oxazolone, OX, Sigma) was 
dissolved (25 mg/ml) in 4:1 acetone:olive oil 
(AOO). Mice (n=3 per group) received 
epicutaneous application of either 25 µl of 2.5% 
OX or AOO on the dorsum of the ear on day 0 
(70). The draining auricular lymph nodes were 
removed three days later and the induced 
proliferative response was assessed as previously 
described. Briefly, 5 x 10
5
 cells per well were 
cultured in RPMI-1640 medium with glutamate 
(Gibco®, Invitrogen Ltd, Paisley UK), 
supplemented with 0.5mM sodium, in round-
bottomed 96 well plates overnight at 37°C in a 
humidified atmosphere of 5% CO2.In the presence 
of 1 μCi3H-thymidine (PerkinElmer, MA, USA) 
per well. DNA synthesis was estimated using beta 
scintillation counting as above Animals received 
daily i.p. injections of either vehicle or JW47 from 
day zero to three (14,70). Results are expressed as 
mean± SEM thymidine incorporation counts per 
minute (CPM) 
Induction of relapsing-progressive EAE. 
Mice were injected subcutaneously (s.c.) with 1mg 
freeze-dried mouse spinal cord homogenate (SCH) 
in Freunds adjuvant on day zero and seven as 
described previously (71). After the initial 
paralytic disease and subsequent remission, a 
relapse was induced by a further injection of SCH 
in Freunds incomplete adjuvant on day 28  to 
induce a relapse 7 days later (71). Studies were 
randomised, blinded and powered as described 
previously (71). Neurological scores were graded 
as 0 = normal; 1 = limp tail, 2 = impaired righting 
reflex, 3 = hindlimb paresis, 4 = complete 
hindlimb paralysis, and 5 = moribund/death (71). 
Results are expressed as mean ± SEM maximum 
or minimum neurological score and mean day of 
onset± SD. The clinical scores are presented as the 
mean daily neurological score ± standard error of 
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the mean (SEM). Differences in clinical scores 
were assessed using non-parametric, Mann 
Whitney U statistics(71). Motor control and co-
ordination was assessed on an accelerating (4 – 40 
rpm, accelerating at 6rpm/25s) RotaRod (ENV-
575M, Med Associates Inc, St. Albans, VT, USA) 
as described previously (71). This was performed 
one day before induction of relapse and at the 
termination of the experiment on day 45. RotaRod 
assessment was performed blinded to treatment. 
Animals were randomised to vehicle or treatment 
based on their RotaRod scores. Results are 
expressed as mean ± SEM time that animals 
maintained rotarod activity. Differences in rota 
activity; and quantitative neurofilament ELISA 
was assessed using a Students t test incorporating 
tests for equality of variance using Sigmaplot 
(Systat Software, Inc., San Jose, USA) (71). 
At the end of the experiment the spinal 
cord was removed and an enzyme linked 
immunosorbent assay (ELISA) for heavy chain 
neurofilament on spinal cord was performed and 
total nerve content of each spinal cord was 
estimated following calibration against 
neurofilament protein standards as described 
previously (72); (71). 
 Neurofilament ELISA. 
Neurofilament level as a validated correlate of 
spinal cord axonal content as determined by 
histology was determined as followed. Spinal 
cords were collected from the spinal columns of 
untreated (n=11) and JW47 1 mg/kg treated 
(n=13) animals at the second remission phase of 
disease post relapse at day 45 post disease 
induction. Tissues snap frozen and stored at -80ºC 
prior to homogenisation. Tissues were 
homogenised in a glass homogeniser in 1ml/100 
mg of spinal cord tissue wet weight 
homogenisation buffer (0.2 mM PMSF, 1mM 
EDTA, 1mM EGTA, 4M Urea, 10 mM Tris-HCl 
Sigma UK, pH 7.2,) plus 1:100 HALT protease 
inhibitor cocktail (Thermo Fisher, UK) and further 
homogenised by sonication twice for 10 seconds 
(Cole-Parmer Instruments, USA). Samples were 
spun down at 13,000 rpm in a bench top centrifuge 
(Eppendorf, UK) and the supernatant was 
collected and stored at -80ºC prior to 
neurofilament determination. Samples were 
thawed on ice and an enzyme linked 
immunosorbent assay for heavy chain 
neurofilament was performed. Briefly, a 96 well 
plate was coated overnight at 4C with capture 
antibody (1:5000 SMI-35 anti-neurofilament H. 
Covance Inc. Cambridge Bioscience, Cambridge, 
UK) in coating buffer (0.15M Na2CO3, 0.35M 
NaHCO3, Sigma, UK, pH 9.6. Following one wash 
in wash buffer (150mM NaCl, 10mM Tris-HCl, 
0.1% Tween 20, Sigma, UK pH 7.5), non-specific 
binding was blocked by incubation with 5% 
bovine serum albumin (Sigma, UK) in wash buffer 
for 1 hour at room temperature. Following a wash 
step, samples and standards (Porcine 
neurofilament heavy chain, Chemicon  
International, UK) were diluted in wash buffer 
with 1% bovine serum albumin and incubated on 
the plate for 1 hour at room temperature. 
Following 5 wash steps, the detector antibody was 
applied (1:1000 rabbit anti-NF200, Sigma, UK) 
and incubated for a further hour at room 
temperature. The plate was washed 5 times and the 
reporter antibody was applied (1:1000 swine anti-
rabbit HRP conjugate, DAKO, UK).Following a 
final 5 washes, tetramethylbenzidine substrate 
(Sigma, UK) was applied and colour production 
measured on a BioTek Synergy HT (USA) plate 
reader at 450nm. 
The protein content of the samples was determined 
by micro-BCA assay (Pierce, Thermo Fisher, UK 
and axonal neurofilament levels in each were 
calculated as μg neurofilament per mg of total 
protein in each sample. 
 SMI32/SMI35 Ratio. A 96 well 
plate was coated with either SMI35 anti-
phosphorylated Nf-H or SMI32 anti-non-
phosphorylated Nf-H which is a marker of axonal 
damage/dystrophy (Covance Inc. Cambridge 
Bioscience, Cambridge, UK) antibodies at 1;5000 
dilution as above. Due to the nature of the epitope, 
an absolute standard for SMI32 reactive 
neurofilaments was unavailable. Nf-H
SMI32
 was 
therefore presented as a proportion of total 
neurofilament as measured by absorbance level 
and corrected for total protein levels in each 
sample. 
Study approval. All animal procedures 
were approved by the local ethical review 
processes and Government Inspectors in 
accordance with UK Animals (Experimental 
Procedures) Act 1986, which incorporates 
directive 2010/63/EU. Experimental details, 
including: randomisation; powering and blinding, 
to conform with the ARRIVE (Animals in 
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Research: Reporting In Vivo Experiments) 
guidelines have been reported previously (71).  
 
RESULTS  
Design and synthesis of a selective CypD 
inhibitor: We required a molecule with the 
following profile: a) good CypD potency, b) 
selectivity for CypD over other cellular 
cyclophilins by mitochondrial targeting, c) 
significant brain levels indicating an ability to 
target MS lesions. d) low immunosuppressive 
activity and e) a better cytotoxic profile than CsA. 
CsA is famously non-druglike in terms of small 
molecule parameters such as Lipinksi’s rules of 
five, however the macrocyclic structure has been 
proposed to cancel out some of the non-druglike 
features such as excessive hydrogen bonding (73).  
In chemical terms the compound is an uncharged, 
11 amino acid, macrocyclic peptide. It is lipophilic 
with a measured logP of 2.7 (74). 
A ternary complex of CsA, CypA and 
calcineurin is required to trigger the 
immunosuppressive response via inhibition of 
NFAT dephosphorylation(75). Residues 3-7 are 
available from the Cyp–cyclosporin complex to 
bind calcineurin. The ternary complex is closely 
packed and less tolerant of changes than for Cyp 
binding alone. The crystal structure of SmBzCsA 
(Fig. 1C) reveals that substitution at the [Sar]
3
 
position does not affect cyclophilin binding but 
blocks calcineurin binding(76).  We chose to 
modify CsA at the [Bmt]
1
 side chain where we 
predicted that substitution would have a similar 
negative effect on immune-suppression. As the 
activation of calcineurin is also proposed to 
mediate some of the cytotoxic effects of CsA we 
anticipated that selective molecules would 
improve the toxicity profile while additional 
selectivity for CypD over the cytoplasmic 
cyclophilins would provide further gains.  
The CsA binding cleft in cyclophilins is 
highly conserved and mitochondrial targeting 
provides a convenient way to obtain selectivity for 
the mitochondrial CypD.  A variety of compounds 
have been suggested to localize to mitochondria. 
Mostly these are lipophilic cations such as TPP
+
, 
but other cations are known (77). We were 
attracted by the possibility of utilizing quinolinium 
cation as a targeting group for several reasons, 
including its small size, and chemical simplicity. 
The cation is also present in dequalinium, a topical 
antibiotic that can also be given in vivo 
(US4,946,849, Makler, August 7, 1990)(78). We 
utilized SmBzCsA as a non-immunosuppressive, 
non-targeted control (Fig. 1B)(36,76). We also 
designed the chemical linker to be small and to be 
a hydrocarbon chain to minimize any effects on 
membrane permeabililty.  
Synthesis. We employed olefin metathesis 
as a direct and relatively mild way to alter the 
natural structure of CsA. The synthesis of the 
[Bmt]
1
 linked CsA derivatives is outlined in Fig. 
1A.  Olefin cross-metathesis using the Grubbs-
Hoyeda second generation catalyst and the 
quinolinium substituted olefin yields the target 
analogue JW47.  The synthesis of the required 
quinolinium olefin is also shown.  Shorter linkers 
did not provide effective couplings in the 
metathesis reaction (not shown).  Synthesis of the 
fluorescein-PEG-CsA probe for the fluorescence 
polarization assay was conducted using cross-
metathesis, followed by hydrolysis, and successive 
amide coupling steps to provide the desired 
compound (Supplementary Fig. S1). 
X-ray analysis of a CypD JW47 complex. 
In order to determine the precise binding mode of 
JW47 to CypD we determined the X-ray structure 
of the complex to 1.1 Å resolution.  We utilized 
the protein sequence of CypD (ppif) with a K133I 
mutation, which enhances crystallisation without 
significantly affecting activity(48). Crystals were 
grown with the hanging drop method and the 
CypD structure 2z6w used as the search model 
with CsA removed. The electron density for JW47 
in the active site is shown (Fig. 2A), with the 
structure of JW47 modelled in green. 
Crystallographic parameters are shown in Table 1. 
The core of the macrocycle is almost identical to 
that of CsA itself while the pendant quinolinium 
group can adopt two poses (Fig. 2B).  In both 
poses the position of the quinolinium group is 
partially stabilised by crystal contacts with a 
symmetry related molecule.  In one of the poses 
the1-(pent-4-enyl)quinolinium (salmon colour) 
extends back over the macrocycle and makes an 
intramolecular hydrophobic contact with MeLeu
4
 
of JW47.  In the other pose (magenta) the 1-(pent-
4-enyl)quinolinium moiety extends in the opposite 
direction to lie along the surface of the CypD 
making hydrophobic contacts with Ala 103, 
Gly104, and Pro105.  
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Cyclophilin enzyme binding.  A 
fluorescence polarization assay was used to 
determine cyclophilin binding. CsA gives binding 
constants of Ki 1.4 nM for CypD and 22.5 nM for 
CypA.  These affinities are broadly in agreement 
with data from other laboratories (59,60).  The 
CsA analogue, SmBzCsA also demonstrated 
potency in this assay with Ki CypD 236 nM and 
Ki CypA 202 nM (Table 2) consistent with our 
data utilizing the classical chymotrypsin based 
system(36). JW47 showed similar binding to 
SmBzCsA at Ki CypD 202 nM, and Ki CypA 236 
nM.  Representative dose response curves for 
CypD and CypA are shown (Fig. 2C and D).  
The quinolinium group localizes 
fluorescein to mitochondria. To confirm that 
quinolinium cation can localize cargo to 
mitochondria we took a membrane impermeant 
dye, carboxyfluorescein and conjugated it to 
mitochondrial using an alkyl linker 
(Supplementary methods).  The linked dye 
diffused into cells (though some remained 
extracellularly) and co-localised with 
tetramethylrhodamine methyl ester demonstrating 
the mitochondriotropic properties of quinolinium 
(data not shown).  
JW47 is a highly potent inhibitor of Ca
2+
 
mediated PT pore formation. In order to assess the 
efficiency of compounds on Ca
2+
 mediated PT 
pore formation we measured calcium retention 
capacity (CRC) of isolated mouse liver 
mitochondria. The Ca
2+
 concentration in the extra-
mitochondrial solution was measured using the 
membrane impermeable low affinity fluorescent 
Ca
2+
 sensitive dye Fluo-5N following repeated 
addition of Ca
2+
 boluses (10 µM). Energised 
mitochondria take up Ca
2+
, resulting in a declining 
fluorescent signal following the Ca
2+
 bolus 
induced peak. Mitochondria take up and buffer 
Ca
2+
 up to a threshold when intramitochondrial 
[Ca
2+
] reaches threshold to induce PT. This results 
in loss of mitochondrial membrane potential 
preventing further Ca
2+
 uptake, resulting in lack of 
Ca
2+
 buffering, represented by stepwise increase in 
extramitochondrial [Ca
2+
] at each Ca
2+
 addition 
(Fig. 3A). The amount of Ca
2+
 required to induce 
PT characterizes its Ca
2+
 sensitivity and defines 
mitochondrial CRC. Inhibition of CypD, the Ca
2+
 
sensor of PT, thus leads to increased CRC. JW47 
inhibited Ca
2+
-induced PT (i.e. increased CRC) 
with significantly higher potency as compared to 
CsA and the non-immunosuppressive inhibitor 
SmBzCsA. JW47 showed half-maximal inhibition 
at ~10 nM as compared to ~40nM for CsA in the 
CRC assay (Fig. 3B). These results show that 
JW47 is approximately a four-fold more potent 
inhibitor of Ca
2+
 mediated PT pore opening than 
CsA. In order to confirm that JW47 selectively 
targets CypD to reduce Ca
2+
 sensitivity of PTP 
formation, the efficiency of the compound was 
tested on mitochondria isolated from CypD 
knockout mice. Neither CsA nor JW47 had any 
effect on CRC from CypD KO mice (Fig. 3C), 
whereas CRC in the mitochondria from WT mice 
was significantly increased by both compounds, 
proving that JW47 inhibits PT pore opening via 
binding to CypD. 
JW47 has a wide safety window over 
effects on mitochondrial membrane potential or 
oxidative phosphorylation. To assess the potential 
adverse effects of JW47, we measured 
fundamental mitochondrial functional parameters 
both in cultured rat neurons and in isolated 
mitochondria, and compared the effects of CsA 
and JW47 above concentrations causing maximal 
inhibition of the PT pore (>200 and 40 nM, 
respectively). 
Neither mitochondrial membrane potential (Fig. 
4A,B), oxygen consumption (Fig. 4C, D) and ATP 
production (Fig. 4E, F) were affected by 
supramaximal JW47 (up to 200 nM) or CsA (up to 
1 μM) in either models. JW47 inhibited neuronal 
mitochondrial membrane potential only at ~25 
times higher concentrations (1 μM), as compared 
to that of its maximal inhibitory effect (40 nM) on 
the PT pore.  
Estimation of cellular CypA activity using 
an HIV based cellular assay. To test cellular 
cyclophilin selectivity of JW47 we conducted a 
human immunodeficiency virus (HIV-1) based 
cellular assay responsive to CypA inhibition. HIV-
1 infection of cell lines can be inhibited by the 
expression of an artificial antiviral protein, 
comprising the RBCC domains of owl monkey 
tripartite motif-containing protein 5 (TRIM5) 
fused to human CypA (TRIM-CypA). TRIM-
CypA inhibited viral infection by 32 fold in the 
absence of drug (Fig. 5A). CsA rescued infectivity 
through CypA inhibition whereas JW47 rescued 
infectivity poorly and only at concentrations >10 
µM (Fig. 5B). A drop to infectivity in non-
restricting cells was due to drug toxicity at 5 µM 
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CsA and above. JW47 showed no evidence for 
toxicity at any of the concentrations tested.  
Activity against drug and anion 
transporters. The ability of the compounds to 
affect human pgp (ABCB1) drug transporter 
activity was assessed using a bioluminescence 
assay.  The standard inhibitor verapamil at 100 
µM showed a 40% reduction in luminescence 
(Fig. 5C). Despite being noted as a pgp 
inhibitor(79) CsA showed only a 16% inhibition at 
100 µM.  JW47 showed less inhibition than CsA, 
8% at 100 µM (Fig. 5C).  Activity against organic 
anion transporters OATP1B1 and OATP1B3 has 
been linked to drug induced unconjugated 
hyperbilirubinaemia in patients receiving 
alisoporivir(80). JW47 demonstrated 7 - 8 fold less 
inhibition of β-estradiol-17-β-D-glucuronide 
uptake for the OATP1B1 transporter than CsA 
(2.56 ± 0.47 µM versus 0.44 ± 0.084 µM for CsA). 
Similarly for the OATP1B3 transporter JW47 
showed fourfold less activity than CsA for 
inhibition of CCK-8 transport (IC50 0.20 ± 
0.11versus 0.82 ± 0.07 µM). 
Cytotoxicity in HepG2 cells. HepG2 cells 
represent a convenient model for exploring 
hepatotoxicity and can be used to estimate 
multiple cell health parameters simultaneously.  
JW47 showed less toxicity in all measures 
examined, most notably cytochrome C release 
(Fig. 5D).  
Pharmacokinetics. JW47 
pharmacokinetics was determined in normal ABH 
mice at 10 mg/kg i.p. at 2 and 4 h. JW47 showed 
high plasma levels of 10.1 µM at 2 h (Table 3) and 
appreciable, though much lower brain levels (13.2 
nM). A 10 mg/kg dose was used to enable 
detection in brain. This is broadly comparable with 
CsA in rodents(79). 
JW47 is markedly less immunosuppressive 
than CsA. The inhibitory effect of JW47 on T cell 
responses was examined in vitro. Concanavalin A 
and mitogenic CD3/CD28 monoclonal antibodies 
induce mitogenic T cell proliferative responses 
that were inhibited by CsA typically in the 1-10 
nM range (Fig. 6 panels A to C). JW47 only 
exhibited marked immunomodulation in the 1-10 
µM range and was cytopathic at 100 µM. 
Similarly, JW47 exhibited markedly less 
immunosuppressive activity compared to CsA in 
an antigen-driven proliferation assay using myelin 
peptide (myelin oligoglycoprotein residues 35-55) 
antigen-induced T cell proliferation. 
 
The dominant pathogenic antigen in spinal 
cord homogenate-induced disease in ABH mice is 
a hydrophobic residue in proteolipid protein that 
does not produce robust T cell proliferative 
responses in vitro. Therefore, to identify non-
immunosuppressive doses of potential 
neuroprotective compounds for use in models of 
MS(14,70) we employed a model using 
epicutaneous application of the ear skin sensitizer, 
oxazolone, to induce a T cell proliferative 
response in the draining auricular lymph node 
peaking 3 days later (Fig. 7) (70). Dose-response 
of JW47 in this contact hypersensitivity model 
showed: daily injection of 1 mg/kg and 0.1 mg/kg 
i.p. had no effect, while 10 mg/kg i.p. inhibited the 
T cell response. CsA was immunosuppressive 
(Fig. 6D) at doses known to inhibit T cell 
proliferation and EAE (70). Daily dosing of 1 
mg/kg i.p. JW47 was therefore chosen as a non-
immunosuppressive dose for in vivo studies.  
JW47 induces neuroprotection in vivo and 
slows the accumulation of disability in an 
experimental model of multiple sclerosis.  
The EAE model of multiple sclerosis can be used 
to assess both inflammatory and 
neurodegenerative aspects of the disease (81). It 
has previously been shown that the severity of 
neurological disease during disease worsening, 
associated with weight loss, is directly correlated 
to the degree of immune infiltration into the spinal 
cord(81-83). Immunosuppression that inhibits the 
incidence or severity of disease is usually 
associated with a reduction in the histological 
detection of infiltrates, demyelination and axonal 
loss (81-83).Clinical disease was assessed by 
scoring neurological signs. In addition to this 
subjective read-out, objective motor outcomes 
were detected by assessing loss of motor-co-
ordination on an accelerating rotorod, which has 
previously been shown to exhibit a strong positive 
correlation with spinal nerve content (71).  JW47 
was administered daily at 1 mg/kg i.p. shortly 
before the anticipated onset of relapse. This failed 
to inhibit the development or the severity of 
relapse, which would occur with an T cell 
immunosuppressive agent (84), limited the 
accumulation of disability due to the inflammatory 
penumbra (Fig. 8A). Thus there were no 
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differences in the incidence of disease (14/14 
JW47 vs. 12/12 vehicle); the onset of induced 
relapse following injection of SCH in Freunds 
adjuvant on day 28 (34.5 ± 0.7 days JW47 vs. 34.1 
± 0.8 days vehicle) or maximal severity disease 
score (3.9 ± 0.1 JW47 vs. 3.9 ± 0.1 vehicle). 
Animals relapsing during treatment with daily 
50mg/kg CsA developed clinical disease with a 
score of 3.0 ± 0.4 (n=7), which is significantly 
(P<0.05) lower than found with either vehicle of 
JW47-treatment and is indicative of 
immunosuppression. Treatment with an 
immunosuppressive agent, such as 250µg CD4-
depleting (YTS191) monoclonal antibody or other 
immunosuppressive agents, which are optimized 
for treatment at this late stage will completely 
eliminate relapse (70). Therefore there was no 
clinical evidence that JW47 was inducing overt 
immunosuppression in this paradigm. However, 
whilst the differences in minimal clinical score 
during the first remission before treatment were 
not different (0.6 ± 0.1 JW47 vs. 0.6 ± 0.1 
vehicle), following induced-relapse JW47-treated 
animals accumulated less deficit as a consequence 
of the attack and demonstrated a significant 
(P<0.001) better recovery during the second 
remission (minimal neurological score 1.4 ± 0.3 
JW47 vs. 3.1 ± 0.1 vehicle (P<0.001). This 
subjective outcome was supported by objective 
rotarod activity outcomes (Fig. 8B). Animals 
exhibited comparable rotorod activity on day 27 
during the first remission (168.8 ± 21.8s JW47 vs. 
161.1 ± 16.0s vehicle) but there was significantly 
(P<0.001) less loss of motor co-ordination 
following treatment with JW47 (Fig. 8B). During 
the second remission after relapse JW47-treated 
animals maintained activity on an accelerating 
rotorod for 135.0 ± 42.9s compared to only 46.3 ± 
10.1s in vehicle treated animals. This activity 
strongly correlates with spinal nerve content in 
this assay (71), and it was found that JW47 lost 
significantly (P<0.01) less nerves(Fig. 8C) and 
axons (Fig. 8D) within the spinal cord than 
vehicle-treated animals, which was measured 
using a quantitative neurofilament ELISA. The 
SMI 35 antibody stains neurofilaments with high 
and low degrees of phosphorylation and reveals 
thick and thin axons. SMI-32 does not stain thin 
axons.  The degree of neurofilament 
phosphorylation is modulated by myelination (85) 
so our readout directly quantifies loss of small 
axons and by inference demyelination. This assay 
system has been validated against the histological 
detection of nerve loss during EAE (72,83) and is 
a biomarker of neurodegeneration in MS.  Thus 
JW47 exhibits neuroprotective potential and can 
inhibit loss of nerves due to the inflammatory 
penumbra during EAE.  
 
Discussion 
The permeability transition pore is linked to a 
necrotic cell death but has been hitherto 
underexploited as a therapeutic target.  The most 
well-known modulator of the pore, CypD is 
located on the inner mitochondrial membrane and 
is resistant to blockade by small molecules. CsA is 
the standard pan-cyclophilin inhibitor but it shows 
no selectivity for CypD and exhibits significant 
cytotoxicity.  We have previously shown that CsA 
can be targeted to mitochondria using the well-
known TPP
+
 cation. Unfortunately, 
triphenylphosphonium attached by long alkyl or 
PEG linkers increases the overall lipophilicity and 
molecular weight of the conjugate substantially 
and adversely affects pharmaceutical properties. In 
this study we utilized quinolinium attached by a 
short alkyl chain as a mitochondrial targeting 
cation with a minimal effect on molecular weight 
and lipophilicity. Olefin cross-metathesis enabled 
functionalization of CsA using mild conditions 
which did not affect the sensitive functionality of 
the cyclic peptide (86). Using this methodology 
we identified JW47 as a prototype inhibitor. In 
isolated mitochondria, JW47 delayed opening of 
the PT pore and was more active than CsA. 
Detailed measures of oxidative phosphorylation 
indicated that JW47 only affected cellular ATP 
production at supramaximal concentrations but not 
at the effective concentration (40nM), or the 
lowest maximally effective concentration (200 
nM).  In cortical neurons, mitochondria were not 
affected by 40nM JW47, but were significantly 
depolarized by 1µM JW47. The greater effect of 
JW47 in mitochondrial Ca
2+
 buffering compared to 
CsA indicates that quinolinium is effective in 
directing the drug to mitochondria in accordance 
with its more negative electro-potential and in 
agreement with the Nernst equation(87). JW47 has 
less intrinsic CypD binding than CsA, but is a 
more potent PT pore inhibitor. In addition, in 
isolated mitochondria from CypD knock out mice, 
JW47 had no effect on Ca
2+
 mediated PT, proving 
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that its principal mechanism of action is mediated 
by CypD binding.  In a system designed to detect 
restriction of HIV replication via CypA JW47 
showed no activity in contrast to both CsA and 
SmBzCsA indicating that JW47 has minimal 
ability to inhibit CypA in cells. Drug transporter 
studies on JW47 indicate less propensity to cause 
bilirubinemia via inhibition of the bilirubin 
transporter OATP1B1 in comparison to CsA itself 
and an analogue Alisporivir(88). A multi-
parameter study of JW47 in hepatocellular 
carcinoma derived HepG2 cells showed less 
toxicity than CsA (89) with perhaps a surprising 
drop in mitochondrial toxicity, despite the 
expected sequestration of the ligand to 
mitochondria ( 88) 
EAE is a T cell-mediated, autoimmune model of 
MS, which can develop relapsing autoimmunity 
and progressive neurodegeneration (20,81,84) 88 
should be 84. Studies using transgenic mice in the 
EAE model have shown that the PT pore pathway 
can determine neurodegeneration, independently 
of the peripheral immune response (20,21,90).  
Whilst CsA can prophylactically inhibit the 
generation of EAE, it is therapeutically less 
effective during spontaneous-relapsing EAE and 
was did not inhibit relapsing MS also (70,91). 
Furthermore, the nephrotoxicity of CsA also 
limited its clinical utility in MS (39). Progressive 
MS, is associated the accumulation of nerve loss 
and disability, shows minimal response to 
peripheral immunosuppression and is currently 
untreatable (92). It was found that doses of JW47 
could be selected to induce neuroprotection 
without causing overt T cell immunosuppression 
We chose ELISA detection of total spinal cord 
nerve content as a robust non-biased way to fully 
quantify nerve loss (and by implication myelin 
content).  This protection may be via direct effects 
on nerves, although it is possible that JW47 also 
exhibited some influence on innate inflammatory 
cells, which are believed to drive progressive 
neurodegeneration. The level of efficacy of Jw47 
is similar to that found previously with other 
neuroprotective agents in this experimental 
paradigm (14), which appear to have some 
predictive value for identifying neuroprotective 
agents in multiple sclerosis(14,93). Relapsing 
disease was not inhibited with JW47, in contrast to 
that, which would occur following T cell 
immunosuppression with drugs used to treat 
relapsing neuroimmunological disease (94). These 
current agents do not however stop progressive 
neurodegeneration (92) and therefore it is believed 
that drugs like JW47 should be used in 
combination with current immunosuppressive 
disease modifying drugs to target the 
neurodegenerative effects that are currently not 
treated. 
 
It is therefore of  interest that CsA-
treatment showed some modest benefit in 
progressive MS(39), and in neuromyelitis optica, 
another immune-mediated demyelinating 
disease(95). This suggests that inhibition of CypD 
activity in humans may offer some clinical benefit 
and would benefit from delivery of a CypD 
selective inhibitor. We anticipate that JW47, 
which is more selective and less toxic in cells 
would be better tolerated than CsA in vivo.  
CsA is thought to be excluded from the 
CNS by adenosine binding cassette drug 
transporters, such as an ABCB1, ABCC1, ABCC4 
and ABCG2 which are present in the brain 
(14,96,97). JW47 exhibited limited activity as 
ABCB1 substrate compared to CsA and could be 
detected in the brain of normal animals. A 
pharmacokinetic experiment with JW47 showed 
potential for in vivo evaluation with high plasma 
levels of JW47 that are within the active in vitro 
dose range and significant though lower brain 
levels. Whilst brain levels may be higher at Cmax, it 
is also probable that brain levels and importantly 
spinal cord levels may be significantly higher in 
animals with active and chronic EAE, which 
exhibit mainly spinal cord disease, due to 
alterations in metabolism and blood-brain barrier 
breakdown that occurs in EAE and MS (11,71,98). 
Furthermore, CNS adenosine binding cassette drug 
transporters, notably p-glycoprotein (ABCB1) are 
down-regulated from vasculature such that 
compounds, even ABCB1-substrates, can be 
selectively targeted to lesions, despite poor 
apparent global CNS penetration (14).  Further 
studies to determine the oral bioavailability, 
pharmacokinetic/ pharmacodynamics and 
toxicology of JW47 and related molecules are 
warranted. The action of JW47 demonstrates that 
pharmacological inhibitors of the PT pore are 
neuroprotective in EAE, as predicted using genetic 
ablation studies of CypD (20) and P66ShcA in the 
PT pore pathway (21,99) and may provide a 
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treatment for neurodegeneration and progression 
of disability during relapsing–remitting and 
progressive MS and other neurological diseases. 
In summary we have shown that 
quinolinium is an effective mitochondrial targeting 
group, the CsA tagged molecule is less cytotoxic 
than CsA and shows little ability to interact with 
cytoplasmic proteins.  In mitochondria JW47 is a 
more potent inhibitor of pore opening than CsA, 
and does not affect mitochondrial function at a 
concentration of maximal inhibition.  Furthermore 
JW47 demonstrates a pronounced neuroprotective 
effect in vivo and should be a useful tool for 
investigation of the role of the PT pore in other 
neurodegenerative conditions and in models of 
ischaemia–reperfusion injury. The quinolinium 
cation is smaller and is more amenable to 
pharmaceutical optimization than TPP
+
 and we 
anticipate that it will become a useful addition to 
the toolbox of mitochondrial targeting groups. 
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FOOTNOTES 
The abbreviations used are: CRC, calcium retention capacity; CypD, cyclophilin D; CypA, cyclophilin A; 
CsA, cyclosporine; FP, EAE, experimental autoimmune encephalomyelitis fluorescence polarization; PT, 
permeability transition; MS, multiple sclerosis; TPP
+
, triphenylphosphonium. 
 
FIGURE LEGENDS 
 
Figure 1. A Synthesis of [Bmt-1] and [Sar-3] substituted analogues by olefin Cross-metathesis and 
alkylation. Reagents i) DCM, Hoveyda-Grubbs catalyst, 2
nd
 generation, reflux, 30 hr. ii) LDA, allyl 
bromide. B Structure of SmBzCsA, C The crystal structure of SmBzCsA (pdb code 4IPZ) is shown 
bound to CypA (solid magenta surface).  The aligned structure of CypD (pdb code 5a0e) is shown as 
a wire mesh.  Amino acids 9 to 2 are involved in cyclophilin binding. The [Bmt]1 residue (pink) side 
chain and the [Sar]3 substituent do not affect cyclophilin binding.  
 
Figure 2.  A Crystal structure of JW47 in complex with CypD and its effect on Ca
2+
 induced PT., electron 
density of JW47 in the CypD catalytic site is shown as a wire mesh with JW47 modelled into the density 
as a ball and stick model (green).  B, JW47 adopts two poses in the crystal structure shown in orange and 
magenta.  The orange pose illustrates a possible stabilizing interaction with Ala103, Pro105, and Lys125. 
Surface in green is generated from the chain that co-crystallised with this pose. Note that Lys125 also 
adopts 2 conformations. C Fluorescence polarization assay for cyclophilin binding obtained using a 
fluorescein labeled CsA probe.  Typical data for CypD is shown.  The concentration of the probe is 45 
nM and the enzyme 40 nM.  mP values are fitted to a dose response curve using Origin. D 
Fluorescence polarization data for CypA. 
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Figure 3 A. Comparison of the effect of JW47, CsA and SmBzCsA on mitochondrial Ca
2+
 retention 
capacity (CRC).  Representative traces of the Ca
2+
 retention capacity assay in isolated rat liver 
mitochondria. Fluo-5N fluorescence was measured in the extramitochondrial solution following repeated 
additions of Ca
2+
 (10 µM, for details see Materials and Methods). Increase in fluorescence indicates loss of 
Ca
2+
 retention due to PT pore opening. Inhibition of PT pore with different compounds (added at 200 nM) 
increases CRC, represented by the delay in increase of fluorescence. B. Dose response curves of JW47 and 
CsA on PT inhibition (expressed as % increase in CRC compared to DMSO treatment). C. Quantification 
of the dose dependent effects of CsA and JW47 on CRC (PT) in liver mitochondria isolated from WT and 
CypD KO animals. Percentage inhibition denotes increase in CRC compared to DMSO treatment, 
normalised to WT.  * p < 0.05 (t-test) 
 
Figure 4. Mitochondrial and cellular toxicological assessment of JW47 and CsA. 
Mitochondrial parameters were measured in rat cortical neurons (A, E) and isolated rat liver mitochondria 
(B-D, F). A, B:Mitochondrial membrane potential was measured in tetramethyl-rhodamine methylesther 
(TMRM) loaded neurons  using ImageXpress MicroXL in (A) and rhodamine-123 loaded isolated 
mitochondria using a fluorescent plate reader in (B). Values in are normalised to DMSO (100%) and 
FCCP (2 µM, 0%) treated samples. * p < 0.05 (one way ANOVA)  C, D: O2 consumption was measured in 
mitochondria isolated from rat liver in the presence of glutamate and malate using Oroboros high 
resolution oxygraph as described in Methods. The effect of compounds on basal, leak (oligomycin, 2.5 
µM) and maximal uncoupled respiration (FCCP, titrated to give maximum effect) is shown, as compared 
to basal, DMSO controls. * p < 0.05 (paired t-tests). E, F: ATP levels in cortical neurons (E) and ATP 
production of isolated mitochondria in the presence of substrates and ADP (F) was measured using a 
luciferase assay as described in Methods. Iodoacetic acid (IAA, 1 mM) and oligomycin (oligo, 2.5 µM) 
was used to show the contribution of glycolysis and mitochondrial ATP synthesis, respectively.  * p < 0.05 
(t-test). (G) In vitro toxicological assessment of CsA and JW47. HepG2 cells were plated and after 24 hr 
the cells were treated with the compounds at a range of concentrations. At the end of the incubation period, 
the cells were loaded with the relevant dye/antibody for each cell health marker and scanned (see 
Methods). Data are shown as EC50 values (µM) ± R
2
, # = no reponse observed at 100 µM 
 
Figure 5: Assessment of in cell CypA binding. CRFK cells transduced with either empty vector (filled 
squares) or TRIM-CypA (open circles) were infected with VSV-pseudotyped GFP-expressing HIV-1 
vector, in the presence of DMSO or increasing concentration of drug. A CsA, B. JW47. Viral infection was 
measured by flow cytometry at 48 hr post infection. Data are the average of three independent 
experiments. C, P-glycoprotein drug transporter activity. Vehicle, verapamil (100 µM) and CsA analogues 
were tested as substrates for p-glycoprotein (Pgp-Glow assay). Results are the mean ± SEM 
bioluminescence measurements from the luciferin reporter. 
Figure 6: The oxazolone contact hypersensitivity test. A low severity in vivo measure of T cell 
proliferation, is used as a rapid screen for immunosuppressive doses of agents.  Oxazolone administered to 
the ear induces an increase in cell number and proliferation in the draining auricular lymph node 
 
 
Figure 7: JW47 exhibits less immunosuppressive activity than CsA.  Mitogenesis in vitro, 4 x 10
-5
 cells 
normal mouse splenocytes were incubated with A 5μg/ml concanavalin A B Mitogenic CD3/CD28 
monoclonal antibodies or C splenocytes from MOG residues 35-55 peptide immunized mice in the 
presence of 5μg/ml MOG peptide with vehicle or compounds for A,B 2 or 4 C days prior to the addition of 
1 μCi3H-thymidine and were harvested 16-20h later and tritiated thymidine incorporation was assessed by 
beta scintillation counting. The results represent the mean ± SEM of triplicate samples. 
D Low doses of JW47 in vivo exhibited no immunosuppressive activity. 25 μl of 2.5% Oxazolone (OX) or 
acetone: olive oil (4:1) vehicle (AOO) was applied to the ear skin of ABH mice on day 0. On day 3 the 
draining auricular lymph nodes of 3-4 mice/group were removed and 5 x 10
5
 cells were cultured overnight 
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in the presence of 1μ Ci 3H-thymidine. Animals were treated with 0.1 ml vehicle or 0.1-10 mg/kg JW47 or 
50 mg/kg CsA. The results represent the mean ± SEM of at least quadruplicate samples. 
 
 
Figure 8. JW47 limits the accumulation of neurodegeneration and disability during relapsing autoimmune 
encephalomyelitis. ABH mice were injected with SCH in Freund’s complete adjuvant on day 0 and 7 to 
induce paralytic EAE. A relapse was induced on day 28 during the first remission, using a further injection 
of SCH in Freund’s incomplete adjuvant. Animals were treated daily from day 33 onwards with either 1 
mg/kg i.p. JW47 (black diamonds. n =14) in ethanol: cremophor: PBS (1:1:18) or vehicle (Grey circles. 
n=12). The results represent A the mean daily neurological score ± SEM; B the mean rotarod activity 
representing the mean ± SEM time before falling/failing to stay on an accelerating rotarod before (on day 
27) or after (on day 45) treatment with either vehicle (Grey bar) or JW47 (Black bar). *** P<0.001 
compared to vehicle treatment. C Axonal content in the spinal cord following treatment of relapsing EAE 
with JW47 1 mg/kg measured as neurofilament level adjusted for total protein content. EAE was induced 
with spinal cord homogenate in complete Freund’s adjuvant on days 0 and 7 and a relapse was induced by 
re-immunisation with spinal cord homogenate in complete Freund’s adjuvant at day 28. Animals were 
randomized according to RotaRod performance score at day 27 to receive either vehicle (Cremophor 
(Sigma, UK), alcohol, phosphate buffered saline 1:1;18) or 1mg/kg i.p JW47 from day 33 p.i. just prior to 
the development of relapse at day 35 until day 47. Animals were killed and the spinal cords removed using 
hydrostatic pressure and axonal content measured using a quantitative neurofilament-specific ELISA. n=11 
untreated, n=13 JW47 treated. Ratio of dephosphorylated (SMI-32 reactive) neurofilament to 
hyperphosphorylated (SMI-35 reactive) neurofilament as measured by ELISA in spinal cord homogenates 
from untreated post-relapse untreated animals; n=11 or JW47 1 mg/kg treated animals n=13   *** P<0.001 
adjusted for total protein level. 
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Table 1. Crystallographic statistics of JW47 
Space group             P212121 
Cell dimensions  
a (Å) 
b (Å) 
38.12 
69.51 
c (Å) 109.17 
Mathews Coefficient 2.03 
Data Statistics All data 
Resolution (Å) 35.99-1.08 (1.11-1.08) 
No. measurements 1255737 (13170) 
No. unique reflections 101679 (2352) 
Completeness (%) 81.5 (24.7) 
Rmeas
 
0.061 (1.279) 
Rpim 0.017 (0.518) 
I/б(I) 22.0 (1.4) 
Refinement Statistics  
R work (%) 
2 
0.0981 
R free (%) 
2
 0.1312 
No. protein atoms 2600 
No. water atoms 304 
No. ligand atoms 194 
Mean overall B value (Å
2
) 15.020 
Data Used In Refinement  
   Resolution range (Å) 35.99 – 1.25 
   Completeness for tange 97.48 
   Number of reflections 75156 
  
r.m.s deviations from ideal
 
 
geometry  
Bond lengths (Å) 0.0224 
Bond angles (
。
) 2.1375 
Ramachadran analysis
3
  
No. in favoured regions (%)
 
316 (97.2) 
No. in allowed regions (%) 
Outliers 
9 (2.8) 
0 (0)  
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Table 2. CypA and CypD binding using Fluorescence Polarization. 
Compound CypA  
Ki (nM) 
K133I CypD  
Ki (nM) 
CsA 22.5 ± 4.3 1.4 ± 1.6 
JW47 504.5 ± 9.2 298.0 ± 17.9 
SmBz 236.2 ± 8.4 202.1 ± 14.1 
 
 
Table 3. Plasma and brain levels of Jw47 in ABH mice following a single 10 mg/kg dose.  
 
Time Plasma Brain 
 µg/mL µM µg/g nM 
2h 13.74 ± 3.84 10.1 0.018 ± 0.0019 13.2 
4h 4.90 ± 0.85 3.60 0.017 ± 0.0016 12.5 
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Supplementary methods  
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-
degeneration in EAE multiple sclerosis.  
Justin Warne, Gareth Pryce, Julia Hill, Xiao Shi, Felicia Lennerås, Fabiola Puentes, Maarten Kip, 
Laura Hilditch, Paul Walker, Michela I. Simone, A.W. Edith Chan, Greg J. Towers, Alun Coker, 
Michael R Duchen, Gyorgy Szabadkai, David Baker*, David L Selwood*. 
 
Contents 
Chemistry           p1 
Preparation of the fluorescein labelled cyclosporine (FP-CsA)   p2 
Preparation of the fluorescein labelled quinolinium     p5 
Chemistry  
All commercially available solvents and reagents were used without further treatment as received 
unless otherwise noted. NMR spectra were measured with a Bruker DRX 500 or 600 MHz 
spectrometer; chemical shifts are expressed in ppm relative to TMS as an internal standard and 
coupling constants (J) in Hz. LC-MS spectra were obtained using a Waters ZQ2000 single quadrupole 
mass spectrometer with electrospray ionisation (ESI), using an analytical C4 column (Phenomenex 
Gemini, 50 x 3.6 mm, 5 μm) and an AB gradient of 50–95 % for B at a flow rate of 1 mL/minute, 
where eluent A was 0.1:5:95 formic acid/methanol/water and eluent B was 0.:5:95 formic 
acid/water/methanol. High resolution mass spectra were acquired on a Waters LCT time of flight 
mass spectrometer with electrospray ionisation (ESI) or chemical ionization (CI).  
 
 
 
 
 
 
  
2 
 
Preparation of the fluorescein labelled cyclosporine (FP-CsA). 
 
 
 
Formation of the vinyl methyl ester derivative (S2) from cyclosporine (S1). 
A solution of cyclosporine (1.00 g, 0.832 mmol), methyl-4-vinylbenzoate (270 mg, 1.665 mmol) and 
Hoveyda-Grubbs 2
nd
 generation catalyst (20 mg, 0.032, 4%) in dichloromethane (4 ml) was stirred at 
reflux (60°C) under nitrogen for 48 hours. T.l.c. analysis (acetone : cyclohexane, 1:1) of the reaction 
mixture showed the presence of the product (Rf 0.63) and complete consumption of the cyclosporine 
A starting material (Rf  0.65). LCMS analysis also confirmed the presence of the product. The 
reaction mixture was pre-absorbed on silica gel and purified by flash column chromatography (ethyl 
acetate : cyclohexane, 1:1 to ethyl acetate to ethyl acetate : methanol, 10%) and the solvent removed 
in vacuo to give a grey solid. The grey solid was then further purified by removing the Grubbs-
Hoveida catalyst by letting it through an SPE-thiol column (eluant: methanol). The solvent was 
removed in vacuo to give the corresponding methyl ester as a white crystalline solid (950 mg, 86.4%).  
3 
 
HRMS (TOF MS ES
+
): found 1344.8726 [M+Na]
+
 C69H115N11O14Na requires 1344.8523;  
max (thin film, KBr): 3466, 3418, 3318 (m-s, bumpy, CON-Hs, OH), 2961, 2935, 2873 (m, alkyl C-
H), 1720 (m, conjugated C=OOMe), 1627 (s broad, bumpy, C=Os, amide I), 1520 (m broad, bumpy, 
C=Os, amide II) cm
-1
;  
NMR δH (CDCl3, 500 MHz): 7.92 (1H, d, J  = 10.5 Hz, NH), 7.90 (2H, d, JArCH,ArCH  = 8.5 Hz, 2 x 
ArHs), 7.64 (1H, d, J  = 8.0 Hz, NH), 7.47 (1H, d, J  = 8.0 Hz, NH), 7.32 (2H, d, JArCH,ArCH  = 8.5 Hz, 
2 x ArHs), 7.06 (1H, d, J  = 7.5 Hz, NH), 6.34–6.24 (2H, m, alkene Hs), 5.62 (1H, dd, J = 10.5, 4.5 
Hz, CH), 5.48 (1H, d, J = 5.5 Hz, CH, residue 1), 5.32-5.22 (2H, m, 2 x CH), 5.07 (1H, d, J = 
11.0 Hz, CH, residue 11), 5.04-4.93 (2H, m, NHCH + CH), 4.90 (1H, dd, J = 10.0, 6.0 Hz, CH), 
4.77 (1H, app-q, J = 7.5 Hz, NHCH), 4.69 (1H, d, J = 14.0 Hz, residue 3, CHReHSi), 4.60 (1H, app-
t, J = 9.0 Hz, NHCH), 4.47 (1H, app-q, J = 7.5 Hz, NHCH), 4.50-4.37 (1H, m, CH), 4.26-4.10 
(1H, broad s, OH), 3.84 (3H, s, CO2Me), 3.76 (1H, app-t, J = 7.0 Hz, CH-OH, residue 1), 3.48, 3.33, 
3.23 (9H, 3 x s, 3 x N-Me), 3.19-3.15 (1H, m, residue 3, CHReHSi), 3.05, 3.04 (6H, 2 x s, 2 x N-Me), 
2.70-2.65 (1H, m, obscured, Ar-CH=CH-CH
A
H
B
), 2.66, 2.62 (6H, 2 x s, 2 x N-Me), 1.87-1.80 (1H, m, 
Ar-CH=CH-CH
A
H
B
), 2.42-2.30, 2.10-0.60 (side-chain alkyl Hs, all residues);  
NMR δC (CDCl3, 125 MHz): 173.84 (C=O), 173.81(C=O), 173.74 (C=O), 173.50 (C=O), 171.54 
(C=O), 171.17 (C=O), 170.50 (C=O), 170.44 (2 x C=O), 170.26 (C=O), 170.18 (C=O), 167.06 (C=O 
ester), 142.44 (ArCq-CH=CH), 132.85 (ArCq-CH=CH), 130.63 (ArCq-CH=CH), 129.88, 125.91 (2 x 
2Cs, 4 x ArCs), 128.19 (Cq-COOMe), 75.05 (CH-CH[side chain]-OH, residue 1), 58.74, 57.97, 
57.56, 55.53 (2 Cs), 55.38 (6 x CH), 51.98 (OMe ester), 50.40 (CH2, residue 3), 48.85, 48.58, 
48.26, 45.18 (4 x CH), 40.50, 38.98, 37.50, 36.38, 36.02 (5Cs, 4 x CH-CH2-CH(CH3)2, residues 4, 
6, 9 and 10; (CH-CH[OH]-CH[side chain]-CH3), residue 1), 39.46 (N-Me), 36.77 (ArCq-CH=CH-
CH2, residue 1), 34.13 (N-Me), 31.58 (N-Me), 31.36 (N-Me), 31.12 (N-Me), 29.81 (N-Me), 29.60 (N-
Me), 29.84, 29.30, 29.14, 25.36, 24.99, 24.90, 24.66, 24.40, 23.81, 23.71, 23.40, 21.92, 21.83, 21.27, 
20.37, 19.87 (15 Cs, 4 x CH(CH3)2 and 4 x CH(CH3)2, residues 4, 6, 9 and 10; 2 x CH(CH3)2, residues 
5 and 11; CH-CH2-CH3, residue 2), 18.72, 18.45 (2 x 2Cs, 4Cs, 2 x valine [CH(CH3)2]), 18.20, 16.90 
(2Cs, 2 x CH-CH3, residues 7 and 8), 16.10 (CH-CH[OH]-CH[side chain]-CH3, residue 1), 9.93 
(CH-CH2-CH3, residue 2). 
 
Formation of the Vinyl acid derivative (S3)  
The methyl ester S2 (260 mg, 0.196 mMol) was stirred in acetone (4 mL) and an aqueous solution of 
sodium hydroxide (2M, 2 mL). After 19 hours a white precipitate had formed and T.l.c. analysis 
(acetone : cyclohexane, 1: 1) showed the presence of one product (Rf  0.17) and some residual starting 
material/impurity (Rf  0.31). The acetone was removed from the reaction mixture and the aqueous 
layer left behind was washed with ethyl acetate. The aqueous layer was acidified with an aqueous 
solution of hydrochloric acid (1M) and washed again with ethyl acetate. The collected ethyl acetate 
layers were dried (magnesium sulfate), filtered and concentrated in vacuo to give a white/pale brown 
hygroscopic solid which was then diluted in acetonitrile and filtered again (eluant acetonitrile). The 
filtrate was finally concentrated in vacuo to give the acid derivative 3 (220 mg, 86%) as a white/pale 
brown hygroscopic solid. 
HRMS (TOF MS ES
+
): found 1330.8366 [M+Na]
+
 C68H113N11O14Na requires 1330.8173. 
max (thin film, KBr): 3418, 3315 (m, bumpy, CON-Hs, OH), 2961, 2936, 2873 (m, alkyl C-H), 1714 
(m, conjugated C=OOH), 1627 (s broad, bumpy, C=Os, amide I), 1520 (m broad, bumpy, C=Os, 
amide II) cm
-1
 
NMR δH (CDCl3, 500 MHz): (500 MHz, CDCl3) δ 3.51 (s, NMe, 3H), 3.37 (s, NMe, 3H), 3.23 (s, 
NMe, 3H), 3.09 (s, NMe, 3H), 3.08 (s, NMe, 3H), 2.68 (s, NMe, 3H), 2.65 (s, NMe, 3H). 
4 
 
NMR δC (CDCl3, 125 MHz): 39.53, 34.19, 31.64, 31.35, 29.88 (2Cs), 29.61 (7 x N-Me). 
 
Synthesis of Fmoc protected intermediate (S4) 
HATU coupling reagent (230 mg, 0.6037 mMol) was added to a solution of the CsA acid S3 
derivative  (395 mg, 0.3018 mMol), chloroform (10 mL) and triethylamine (168 µL) which had been 
stirring for 5 minutes under an atmosphere of nitrogen at room temperature. After a further 5 minutes 
2-[2-(Fmoc-amino)ethoxy ethylamine hydrochloride (257 mg, 0.7083 mMol) was added  to the 
stirring reaction mixture and  left to react for 22.5 hours. LCMS analysis revealed the presence of the 
product in the reaction mixture. The reaction mixture was concentrated in vacuo and successively 
diluted in ethyl acetate and washed with an aq hydrochloric acid solution (1M). The collected organic 
layers were dried over magnesium sulphate, filtered and concentratedin vacuo to give a residue which 
was purified by flash column chromatography (chloroform to chloroform-methanol, 3%) to give the 
Fmoc derivative S4 (406 mg, 83%) as a white hygroscopic solid. 
HRMS (TOF MS ES
+
): found 1638.9775 [M+Na]
+
 C87H133N13O16Na requires 1638.9891. 
δH (CDCl3, 500 MHz): 3.49 (s, NMe, 3H), 3.45 (s, NMe, 3H), 3.34 (s, NMe, 3H), 3.20 (s, NMe, 3H), 
3.06 (s, NMe, 3H), 2.65 (s, NMe, 3H), 2.64 (s, NMe, 3H). 
δC (CDCl3, 125 MHz): 38.98, 33.97, 33.85, 31.77, 29.81 (2Cs), 29.66 (7 x N-Me). 
 
Synthesis of the cyclosporin – PEG- amine derivative (S5). 
To the FmoC protected CsA analogue S4 (97 mg, 0.06 mMol) was added piperidine (0.5 mL), and the 
reaction was stirred overnight at rt. The piperidine was removed on a rotary evaporator and the 
residue purified by chromatography using 5-10% MeOH containing 2% 880 ammonia in CH2Cl2. This 
gave the intermediate amine S5 (26 mg, 0.019 mMol, 31%) as yellow gum.  This was used directly in 
the next step.  
Synthesis of the fluorescein –PEG- CsA derivative (S6). 
To the amine S5 (22 mg, 18.6 mMol), 5/6-carboxyfluorescein (7 mg, 0.0187 mMol) and PyBOP (10 
mg, 19 mMol) in CH2Cl2 (1 mL) was added diisopropylethylamine (9 mg, 13 µL, 76 mMol) and the 
reaction stirred overnight. The volatiles were removed on the rotary evaporator and the residue 
purified using reverse phase chromatography, C18, 5% MeOH to 95% MeOH in water.  This gave the 
product S6 (10 mg, 0.0057 mMol, 48%). 
LCMS (ES+) 1775 (M+Na
+
), 1752 (M+H
+
).  C18 >95%. 
 
1-(10-Bromodecyl)quinolin-1-ium 
 
To a solution of quinoline (0.5 g, 3.87 mmol) in toluene was added 1,10-dibromodecane (1.74 g, 5.81 
mmol) and this mixture was heated to 80°C for 48hrs. The mixture was allowed to cool before 
filtration. The solid was purified by column chromatography, eluting with 0-10% MeOH in DCM. 
The product was isolated as a clear oil (1.26 g, 93%). 
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1H NMR (600 MHz, MeOD) δ 9.41 (dd, J = 5.8, 1.4 Hz, 1H), 9.21 (d, J = 8.3 Hz, 1H), 8.56 (d, J = 9.0 
Hz, 1H), 8.44 (dd, J = 8.2, 1.4 Hz, 1H), 8.31 (ddd, J = 8.8, 7.0, 1.5 Hz, 1H), 8.15 – 8.01 (m, 2H), 5.09 
(t, 2H), 3.43 (t, J = 6.7 Hz, 1H), 2.17 – 2.03 (m, 2H), 1.88 – 1.75 (m, 2H), 1.56 – 1.25 (m, 10H). 
 
1-(10-((3-carboxy-4-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl)oxy)decyl)quinolin-1-ium 
 
To a solution of 5-carboxyfluoroscein (0.065 g, 0.172 mmol) and sodium carbonate (0.04 g) in DMF 
was added dropwise a solution of 1-(10-bromodecyl)quinolinium  (0.06 g, 0.172 mmol) in minimal 
DCM. This mixture was heated to 60°C overnight and was allowed to cool before dilution with DCM 
and washing with 1M citric acid. The organics were dried over MgSO4 and concentrated under 
reduced pressure. The resultant orange solid was purified by column chromatography, eluting with 0-
10% MeOH in DCM. 
The product was isolated as a dark yellow solid (0.082 g, 75%). 
1H NMR (600 MHz, MeOD) δ 9.41 (d, J = 5.3 Hz, 1H), 9.16 (d, J = 8.3 Hz, 1H), 8.56 – 8.50 (m, 2H), 
8.40 (d, J = 8.1 Hz, 1H), 8.35 (dd, J = 8.0, 1.3 Hz, 1H), 8.28 – 8.22 (m, 1H), 8.05 (dd, J = 8.3, 5.8 Hz, 
1H), 8.01 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 6.67 (t, J = 3.5 Hz, 2H), 6.55 (d, J = 8.7 Hz, 
2H), 6.53 – 6.48 (m, 2H), 5.13 – 5.00 (m, 2H), 4.38 (t, J = 6.4 Hz, 2H), 2.19 – 2.01 (m, 2H), 1.92 – 
1.73 (m, 2H), 1.52 – 1.32 (m, 12H). 
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